MétaCan
Menu
Back to cohort
Record W4312088168 · doi:10.1002/alz.063896

SAGE‐718 in Patients With Mild Cognitive Impairment or Mild Dementia due to Alzheimer’s Disease: Results From the Phase 2 LUMINARY Study

2022· article· en· W4312088168 on OpenAlexaboutno aff
Aaron Koenig, Shishuka Malhotra, Jeffrey Wald, Jennifer Petrillo, Katrina Paumier, J Johannensen, Sigui Li, Michael C. Quirk, Emily Freitag, Jim Doherty

Bibliographic record

VenueAlzheimer s & Dementia · 2022
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicPhosphodiesterase function and regulation
Canadian institutionsnot available
Fundersnot available
KeywordsTolerabilityDementiaMontreal Cognitive AssessmentClinical Dementia RatingAdverse effectDigit symbol substitution testMemory impairmentClinical endpointInternal medicineVerbal memoryMedicineCognitionPsychologyPsychiatryDiseaseClinical trialPathology

Abstract

fetched live from OpenAlex

Abstract Background Cognitive impairment has a deleterious impact on patients with AD and their caregivers; new therapies are needed. SAGE‐718, a novel N‐methyl‐D‐aspartate receptor positive allosteric modulator, is being investigated for the treatment of cognitive impairment in patients with neurodegenerative diseases such as Alzheimer’s disease (AD). The LUMINARY Study is designed to evaluate the safety/tolerability of SAGE‐718 and its effects on cognitive symptoms in patients with AD. Method LUMINARY (NCT04602624) is an open‐label, Phase 2 study evaluating SAGE‐718 (3mg QD for 14 days) in patients with AD. Patients (aged 50‐80 years) with Montreal Cognitive Assessment (MoCA) scores of 15‐24 were included. Treatment‐emergent adverse event (TEAE) incidence through Day 28 (primary endpoint), other safety outcomes (secondary endpoints), and cognitive and functional assessments were analyzed. Result Twenty‐six patients (69.2% female; mean age 67 years), with a mean±SD MoCA of 20.7±2.61 were enrolled. Most patients (23/26) had a global Clinical Dementia Rating score of 0.5. Eight TEAEs were reported in 7 (26.9%) patients; all were mild/moderate; 6 were treatment related. No serious adverse events or deaths were reported. At Day 14, improvements from baseline were observed on multiple tests of executive functioning (Digit Symbol Substitution, Multitasking, One Touch Stockings, Spatial Working Memory, and 2‐Back tests) and learning and memory (Pattern Recognition Memory and Verbal Recognition Memory tests). Statistically significant MoCA improvement (+2.3 points vs baseline) was observed at Day 28. No changes in attention/psychomotor speed were observed. Functional assessments also captured notable improvement in some patients (Clinical Global Impressions Scales and Amsterdam Instrumental Activities of Daily Living Questionnaire), particularly on items measuring aspects of complex/higher order activities. Conclusion In this study, SAGE‐718 was generally well tolerated and associated with cognitive and functional improvements in patients with AD. These results support further investigation of SAGE‐718 for the treatment of cognitive impairment associated with AD and other neurodegenerative diseases.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.280
Threshold uncertainty score0.858

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.020
GPT teacher head0.274
Teacher spread0.253 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & DementiaSame topicPhosphodiesterase function and regulationFrench-language works237,207